Foundation Medicine said Wednesday its FoundationOne Liquid CDx test has received approval from the US Food and Drug Administration as a companion diagnostic for Genentech's Rozlytrek (entrectinib).

Foundation Medicine said Wednesday its FoundationOne Liquid CDx test has been approved by the US Food and Drug Administration as a companion diagnostic for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).

A team from Stanford University, Columbia University, the New York Genome Center, and elsewhere has uncovered somatic tandem repeat expansions in tumors from a wide range of cancer types, including a potentially targetable repeat expansion in a subset of kidney cancers.

A new UC San Francisco study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment.

August 11, the Second Roche Pan-Tumor Precision Diagnosis and Innovation Ecology Forum was officially opened at Roche Pharma China Shanghai Campus, where participants discussed solutions for pan-tumor precision diagnosis and treatment.

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy

One of the most promising avenues in treating cancer is to restore our immune system’s ability to recognize and attack cancerous cells.

Pancreatic cancer is a rare, yet elusive and deadly cancer, with a five-year survival rate of about 10%. If the cancer has metastasized, that rate lowers to 3%. And treatment options are extremely limited.

Drugs developed to treat AIDS and HIV could offer hope to patients diagnosed with the most common form of primary brain tumour.

Most human diseases can be traced to malfunctioning parts of a cell — a tumor is able to grow because a gene wasn’t accurately translated into a particular protein or a metabolic disease arises because mitochondria aren’t firing properly, for example.